EasySep™人CD11b正选和去除试剂盒

免疫磁正选与细胞去除试剂盒

产品号 #(选择产品)

产品号 #100-0742_C

免疫磁正选与细胞去除试剂盒

产品优势

  • 易于操作、快速
  • 纯度高达99%
  • 无需分离柱

产品组分包括

  • EasySep™人CD11b正选和去除试剂盒(产品号 #100-0742)
    • EasySep™人CD11b正选去除抗体混合物,0.75 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,2 x 1 mL
  • RoboSep™人CD11b阳性分选与去除试剂盒(产品号#100-0744)
    • EasySep™人CD11b正选去除抗体混合物,0.75 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,2 x 1 mL
    • RoboSep™ 缓冲液(产品号 #20104)
    • RoboSep™过滤吸头(产品号 #21000)

总览

仅需16分钟,即可从新鲜或先前冷冻的外周血单个核细胞 (PBMCs) 或白细胞分离术样本中高效分选或去除人CD11b+细胞。使用EasySep™ 人CD11b正选和去除试剂盒分选得到的细胞能被立即用于下游应用,如流式细胞术、细胞培养或DNA/RNA提取。

使用该试剂盒,通过抗体和磁珠标记CD11b+ 细胞。随后细胞通过EasySep™磁极,无需分离柱得到分离。标记的细胞被保留在管中,而未被标记的细胞被倾倒出。根据您的研究需要,这部分细胞可被保留部分用于下游其他应用。

该试剂盒靶向人CD11b,这是整合素巨噬细胞抗原-1(Mac-1)受体的一个亚基,常被用作髓系细胞标志物。CD11b在单核细胞、巨噬细胞、中性粒细胞以及自然杀伤(NK)细胞亚群表面表达,已知在调控细胞粘附、迁移和吞噬作用中发挥重要作用(Khan SQ et al. Front Med, 2018)。

了解更多关于免疫磁珠EasySep™技术的工作原理。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • Easy 50 EasySep™ Magnet (Catalog #18002) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
粒细胞及其亚群,巨噬细胞,单核细胞,NK 细胞
 
种属

 
样本来源
Leukapheresis,外周血
 
筛选方法
删除,Positive
 
应用
细胞分选
 
品牌
EasySep,RoboSep
 
研究领域
免疫,感染性疾病(传染病)
 

Data Figures

Typical EasySep™ Human CD11b+ Positive Selection Profile

Figure 1. Typical EasySep™ Human CD11b+ Positive Selection Profile

Starting with human PBMCs, the CD11b+ cell content of the isolated fraction is typically 98.6 ± 1.4% after positive selection and 1.7 ± 1.2% after depletion (mean ± SD using the EasySep™ magnet). In the above example, the frequencies of CD11b+ cells in the start, final isolated, and final depleted fractions are 47.8%, 99.4%, and 1.6%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0744
Lot #
All
Language
English
Catalog #
100-0742
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0744
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0744
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0744
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0742
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0742
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (7)

Publications (1)

Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis. V. K. Singh et al. Frontiers in immunology 2022

Abstract

Tuberculosis is a leading cause of death in mankind due to infectious agents, and Mycobacterium tuberculosis (Mtb) infects and survives in macrophages (MФs). Although MФs are a major niche, myeloid-derived suppressor cells (MDSCs) are an alternative site for pathogen persistence. Both MФs and MDSCs express varying levels of leukocyte immunoglobulin-like receptor B (LILRB), which regulate the myeloid cell suppressive function. Herein, we demonstrate that antagonism of LILRB2 by a monoclonal antibody (mab) induced a switch of human MDSCs towards an M1-macrophage phenotype, increasing the killing of intracellular Mtb. Mab-mediated antagonism of LILRB2 alone and its combination with a pharmacological blockade of SHP1/2 phosphatase increased proinflammatory cytokine responses and phosphorylation of ERK1/2, p38 MAPK, and NF-kB in Mtb-infected MDSCs. LILRB2 antagonism also upregulated anti-mycobacterial iNOS gene expression and an increase in both nitric oxide and reactive oxygen species synthesis. Because genes associated with the anti-mycobacterial function of M1-MФs were enhanced in MDSCs following mab treatment, we propose that LILRB2 antagonism reprograms MDSCs from an immunosuppressive state towards a pro-inflammatory phenotype that kills Mtb. LILRB2 is therefore a novel therapeutic target for eradicating Mtb in MDSCs.

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • Easy 50 EasySep™ Magnet (Catalog #18002) • RoboSep™-S (Catalog #21000)
Sample Source Leukapheresis, Peripheral Blood
Selection Method Depletion, Positive
标记抗体
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。